Published in PPAR Res on June 25, 2014
Exploring the emerging complexity in transcriptional regulation of energy homeostasis. Nat Rev Genet (2015) 0.83
Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem (2008) 9.56
The ubiquitin code. Annu Rev Biochem (2012) 7.08
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature (2005) 6.83
Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev (2006) 6.32
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature (2010) 5.01
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (1996) 4.50
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23
Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl (2005) 4.10
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol (2003) 3.04
Is there a code embedded in proteins that is based on post-translational modifications? Nat Rev Mol Cell Biol (2008) 2.64
Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem (1997) 2.31
PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta (2007) 2.10
Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem (2000) 2.10
The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell (2010) 2.06
c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology (1999) 1.60
Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (1996) 1.46
Strategy for comprehensive identification of post-translational modifications in cellular proteins, including low abundant modifications: application to glyceraldehyde-3-phosphate dehydrogenase. J Proteome Res (2008) 1.37
Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun (2000) 1.17
Identification and validation of eukaryotic aspartate and glutamate methylation in proteins. J Proteome Res (2008) 1.16
PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal. Obesity (Silver Spring) (2009) 1.09
Unrestricted identification of modified proteins using MS/MS. Proteomics (2010) 1.00
Identification and quantification of protein posttranslational modifications. Methods Enzymol (2009) 0.99
Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ. Biochim Biophys Acta (2012) 0.91
Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway. J Pharmacol Sci (2008) 0.88
Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue. Biochem Biophys Res Commun (1997) 0.87
Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol (2007) 0.84
Multiple post-translational modifications in hepatocyte nuclear factor 4α. Biochem Biophys Res Commun (2011) 0.82
O-GlcNAc modification of PPARγ reduces its transcriptional activity. Biochem Biophys Res Commun (2011) 0.81
Biochemical Analysis of Histone Succinylation. Biochem Res Int (2017) 0.75